BridgeBio Pharma and Bristol Myers Squibb announced an exclusive license to develop and commercialize BBP-398, an SHP2 inhibitor, in oncology.
FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.Â
BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.
HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
Verana Health and COTA Inc. are merging with the aim of providing data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care.
American Center for Cures and BlueCloudX announced a strategic collaboration aimed at accelerating the development of cures for major diseases while dramatically reducing the time, cost, and complexity of clinical research.
Niowave Inc. and AstraZeneca are expanding their existing supply agreement to a 10-year commitment to deliver actinium-225, following AstraZeneca’s decision to exercise its option to increase capacity.Â
